

Triangle Pharmaceuticals Incorporated

[View the current Triangle Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/10338-Triangle+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/bi corporate/10338-Triangle+Pharmaceuticals+Incorporated.html>)

Contact Details:

4 University Place
4611 University Drive
Durham
NC
27707
United States of America

Tel: 919 493 5980
Fax: 919 493 5925
Email:

Triangle Pharmaceuticals develop new drug candidates primarily in the antiviral area, with a particular focus on therapies for HIV, including AIDS, and the hepatitis B virus ("HBV"). Triangle Pharmaceuticals have an existing portfolio of six licensed drug candidates and one drug candidate for which they have an option to acquire a license. Five of these drug candidates are currently under active development. Triangle Pharmaceuticals goal is to capitalize on our management team's expertise, as well as on advances in virology and immunology, to identify, develop and commercialize new drug candidates that can be used alone or in combination (coactively) to treat serious diseases.

Recent Publications by Triangle Pharmaceuticals Incorporated:



- [Synthesis of \(-\)-DAPD.](#)
*A new synthesis of (-)-DAPD, suitable for large scale development, is...*6th May, 2005
Division of Organic Chemistry, Triangle Pharmaceuticals Inc., Durham,- Nucleosides Nucleotides Nucleic Acids. 2004;23(12):1875-87.
- [Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children.](#)
*Emtricitabine (FTC; Emtriva), a potent deoxycytidine nucleoside reverse...*21st February, 2004
Triangle Pharmaceuticals, Inc., Gilead Sciences, Inc., Durham, North- Antimicrob Agents Chemother. 2004 Jan;48(1):183-91.
- [Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.](#)
*We conducted a randomized, open-label, 10-day study that compared the...*7th January, 2004
Triangle Pharmaceuticals, Durham, North Carolina 27717, USA.- J Infect Dis. 2003 Dec 1;188(11):1652-8. Epub 2003 Oct 31. ([DOI Direct Link](#))

- [Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.](#)
The frequency of human immunodeficiency virus, type 1 (HIV-1) mutations in... 8th July, 2003
Triangle Pharmaceuticals, Inc., a subsidiary of Gilead Sciences, Durham,- J Biol Chem. 2003 May 23;278(21):18971-9. Epub 2003 Mar 21. ([DOI Direct Link](#))
- [Reproductive toxicology profile of emtricitabine in mice and rabbits.](#)
Reproductive and developmental toxicology studies were conducted with... 25th June, 2003
Triangle Pharmaceuticals, Inc, 4611 University Drive, PO Box 50530,- Reprod Toxicol. 2003 Jan-Feb;17(1):95-108.
- [Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature.](#)
Currently, compounds under evaluation for treatment of chronic hepatitis B... 19th June, 2003
Triangle Pharmaceuticals, Inc., Durham, NC 27717, USA.- Hepatology. 2003 Jun;37(6):1309-19. ([DOI Direct Link](#))
- [New synthesis of L-FMAU from L-arabinose.](#)
A new synthesis of 2'-deoxy-2'-fluoro-5-methyl-beta-L-arabinofuranosyl... 26th November, 2002
Division of Organic Chemistry, Triangle Pharmaceuticals Inc., RTP, North- Nucleosides Nucleotides Nucleic Acids. 2002;21(2):155-63.
- [Conformation and local environment of nucleotides bound to HIV type 1 reverse transcriptase \(HIV-1 RT\) in the ground state.](#)
Nuclear Overhauser effect experiments were used to characterize the... 6th August, 2000
Triangle Pharmaceuticals, Inc. Durham, NC, USA.- Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb;19(1-2):13-29.
- [An analysis of the catalytic cycle of HIV-1 reverse transcriptase: opportunities for chemotherapeutic intervention based on enzyme inhibition.](#)
This review describes each of the steps in the HIV-1 reverse transcriptase... 10th June, 2000
Triangle Pharmaceuticals, 4 University Place, 4611 University Drive,- Curr Pharm Des. 2000 Mar;6(5):547-67.
- [Screening for potential toxicity of antiviral therapies.](#)
Nuclear Overhauser effect experiments were used to characterize the... 1st January, 2000
Triangle Pharmaceuticals Inc 4611 University Drive PO Box 50530 Durham NC- Curr Opin Drug Discov Devel. 2000 Jan;3(1):56-62.

Press Releases on Triangle Pharmaceuticals Incorporated:

Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference	24th November, 2009	Quest Diagnostics	<i>MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is</i>
Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference	24th November, 2009	Anadys Pharmaceuticals, Inc.	<i>SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the 21st Annual Piper Jaffray Healthcare Conference on Tuesday,</i>

Prodesse&apos;s ProParaflu+(TM) Assay Cleared for US Marketing by FDA	24th November, 2009	Gen-Probe Incorporated	Michael Watts Vice president, investor relations and corporate communications 858-410-8673 SOURCE Gen-Probe Incorporated SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual
Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference	24th November, 2009	Accumetrics, Inc.	BEIJING, Nov. 24 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of
Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA	24th November, 2009	Lotus Pharmaceuticals, Inc.	

BioNews Results for Triangle Pharmaceuticals Incorporated



- [Durham drug firm finds buyer](#)
Raleigh News & Observer: Nov 17 2009 1:28PM Matching: triangle pharmaceuticals
- [Addrenex acquired by Sciele for \\$29 million, 10x return to investors in three years](#)
Pharma Live: Nov 16 2009 8:31PM Matching: triangle pharmaceuticals
- [Senior Director of Biotechnology at Catalent To Present Course on Bioassays](#)
Express Press Release: Nov 13 2009 3:30AM Matching: triangle pharmaceuticals
- [Executive Appointments at Patheon](#)
Contract Pharma: Nov 11 2009 12:25AM Matching: triangle pharmaceuticals
- [Patheon, Inc. Adds Two Key Industry Leaders To Its Pharmaceutical Development Services Business](#)
Bioresearch Online: Nov 10 2009 5:49AM Matching: triangle pharmaceuticals
- [Patheon, Inc. adds two key industry leaders to its pharmaceutical development services business](#)
Pharma Live: Nov 9 2009 8:20PM Matching: triangle pharmaceuticals
- [Pfizer shuttering 6 of its 20 research-and-development facilities](#)
MarketWatch: Nov 9 2009 5:36PM Matching: triangle pharmaceuticals
- [Pfizer to shutter six out of 20 R&D sites](#)
MarketWatch: Nov 9 2009 5:29PM Matching: triangle pharmaceuticals
- [Written Requests Issued](#)
FDA: Nov 6 2009 2:07PM Matching: triangle pharmaceuticals
- [CED Sets Dates For Upcoming Conference Season](#)
Drug Discovery Online: Nov 5 2009 4:13AM Matching: triangle pharmaceuticals
- [Inspire Pharmaceuticals' revenue jumps](#)
Raleigh News & Observer: Nov 5 2009 10:06PM Matching: triangle pharmaceuticals
- [Gilead: Transforming AIDS](#)
Forbes.com: Oct 30 2009 10:13PM Matching: triangle pharmaceuticals
- [Aerie Pharmaceuticals ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase 2a Study](#)
Earthtimes.org: Oct 22 2009 11:59AM Matching: triangle pharmaceuticals

- [Aerie Pharmaceuticals EUR ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a P](#)
Business Wire: Oct 22 2009 11:41AM Matching: triangle pharmaceuticals
- [Aerie Pharmaceuticals' ROCK Inhibitor, AR-12286, Demonstrates Positive Results in Glaucoma Patients in a Phase](#)
NewsBlaze: Oct 22 2009 5:25PM Matching: triangle pharmaceuticals

Triangle Pharmaceuticals Incorporated Clinical Trials:



- [A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs](#)

Triangle Pharmaceuticals Incorporated Patents:



- 6870048- [Process for the preparation of 2'-halo-.beta.-L-arabinofuranosyl nucleosides](#)
- 5660858- [Cyclosporin emulsions](#)
- 5785975- [Adjuvant compositions and vaccine formulations comprising same](#)
- 5885956- [Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand](#)
- 5922355- [Composition and method of preparing microparticles of water-insoluble substances](#)
- 6081786- [Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens](#)
- 6188988- [Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens](#)
- 6215004- [Method of manufacture of 1,3-oxathiolane nucleosides](#)
- 6228399- [Composition and method of preparing microparticles of water-insoluble substances](#)
- 6410546- [Use of MKC-442 in combination with other antiviral agents](#)
- 6465016- [Cyclosporine particles](#)
- 6518425- [Method of manufacture of 1,3-oxathiolane nucleosides](#)
- 6528515- [Combination therapy to treat hepatitis B virus](#)
- 6576776- [Method of manufacture of 1,3-oxathiolane nucleosides](#)
- 5637625- [Propofol microdroplet formulations](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

